Chapter 1 Understanding the Mechanisms by Which Probiotics Inhibit Gastrointestinal Pathogens

Advances in Food and Nutrition Research

Volumn 56, Issue , 2009, Pages 1-15

  Corr, Sinead C ^a   Hill, Colin ^b   Gahan, Cormac G M ^c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PROBIOTIC AGENT; VIRULENCE FACTOR;

ANIMAL; ANTIBIOSIS; BACTERIUM; DRUG ANTAGONISM; GASTROENTERITIS; GASTROINTESTINAL TRACT; HUMAN; IMMUNOMODULATION; METABOLISM; MICROBIOLOGY; MUCUS; PATHOGENICITY; PHYSIOLOGY; REVIEW; VIRULENCE;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBIOSIS; BACTERIA; GASTROENTERITIS; GASTROINTESTINAL TRACT; HUMANS; IMMUNOMODULATION; MUCUS; PROBIOTICS; VIRULENCE; VIRULENCE FACTORS;

EID: 64749096222     PISSN: 10434526     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1043-4526(08)00601-3     Document Type: Review

References (62)

1. Aiba Y., Suzuki N., Kabir A.M., Takagi A., and Koga Y. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am. J. Gastroenterol. 93 (1998) 2097-2101
2. Altenhoefer A., Oswald S., Sonnenborn U., Enders C., Schulze J., Hacker J., and Oelschlaeger T.A. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol. Med. Microbiol. 40 (2004) 223-229
3. Asahara T., Shimizu K., Nomoto K., Hamabata T., Ozawa A., and Takeda Y. Probiotic Bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157:H7. Infect. Immun. 72 4 (2004) 2240-2247
4. Bakker-Zierikzee A.M., Tol E.A., Kroes H., Alles M.S., Kok F.J., and Bindels J.G. Faecal SIgA secretion in infants fed on pre- or probiotic infant formula. Pediatr. Allergy Immunol. 17 2 (2006) 134-140
5. Bourlioux P., Koletzko B., Guarner F., and Braesco V. The intestine and its microflora are partners for the protection of the host: Report on the Danone Symposium "The intelligent Intestine.". Am. J. Clin. Nutr. 78 (2003) 675-683
6. Carey C.M., Kostryznska M., Ojha S., and Thompson S. The effect of probiotics and organic acids on Shiga-toxin 2 gene expression in enterohemorrhagic Escherichia coli O157:H7. J. Microbiol. Methods (2008) [Epub.]
7. Chang S.K., Dohrman A.F., Basbaum C.B., Ho S.B., Tsuda T., Toribara N.W., Gum J.R., and Kim Y.S. Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer. Gastroenterology 107 (1994) 28-36
8. Collado M.C., Isolauri E., and Salminen S. Specific probiotic strains and their combinations counteract adhesion of Enterobacter sakazakii to intestinal mucus. FEMS Microbiol. Lett. (2008) [Epub ahead of print]
9. Cook S.I., and Sellin J.H. Review article: Short chain fatty acids in health and disease. Aliment. Pharmacol. Ther. 12 (1998) 499-507
10. Corr S.C., Gahan C.G., and Hill C. Impact of selected Lactobacillus and Bifidobacterium species on Listeria monocytogenes infection and the mucosal immune response. FEMS Immunol. Med. Microbiol. 50 3 (2007) 380-388
11. Corr S.C., Li Y., Riedel C.U., O'Toole P.W., Hill C., and Gahan C.G. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl. Acad. Sci. USA 104 18 (2007) 7617-7621
12. Cotter P.D., Hill C., and Ross R.P. Bacteriocins: Developing innate immunity for food. Nat. Rev. Microbiol. 3 (2005) 777-788
13. Darfefeuille-Michaud A., Boudeau J., Bulois P., Neut C., Glasser A.L., Barnich N., Bringer M.A., Swidsinski A., Beaugerie L., and Colombel F. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127 2 (2004) 412-421
14. Di Giacinto C., Marinaro M., Sanchez M., Strober W., and Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-β-bearing regulatory cells. J. Immunol. 174 (2005) 3237-3246
15. Fukushima Y., Kawata Y., Hara H., Terada A., and Mitsuoka T. Effect of probiotic formula on intestinal immunoglobulin A production in healthy children. Int. J. Food Microbiol. 42 1-2 (1998) 39-44
16. Furrie E., Macfarlane S., Kennedy A., Cummings J.H., Walsh S.V., O'Neil D.A., and Macfarlane G.T. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 54 2 (2005) 242-249
17. Galdeano C.M., and Perdigón G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin. Vaccine Immunol. 13 2 (2006) 219-226
18. Gopal P.K., Prasad J., Smart J., and Gill H.S. In vitro properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. Int. J. Food Microbiol. 67 (2001) 207-216
19. Gotteland M., Brunser O., and Cruchet S. Systematic review: Are probiotics useful in controlling gastric colonization by Helicobacter pylori?. Aliment. Pharmacol. Ther. 23 8 (2006) 1077-1086
20. Hart A.L., Lammers K., Brigidi P., Vitali B., Rizzello F., Gionchetti P., Campieri M., Kamm M.A., Knight S.C., and Stagg A.J. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53 (2004) 1602-1609
21. Hedin C., Whelan K., and Lindsay J.O. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: A review of clinical trials. Proc. Nutr. Soc. 66 3 (2007) 307-315
22. Holzapfel W.H., Haberer P., Snel J., Schillinger U., and Huis in't Veld J.H.J. Overview of gut flora and probiotics. Int. J. Food Microbiol. 41 (1998) 85-101
23. Hugo A.A., Kakisu E., De Antoni G.L., and Pérez P.F. Lactobacilli antagonize biological effects of enterohaemorrhagic Escherichia coli in vitro. Lett. Appl. Microbiol. 46 6 (2008) 613-619
24. Ingrassia I., Leplingard A., and Darfeuille-Michaud A. Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells. Appl. Environ. Micorbiol. 71 6 (2005) 2880-2887
25. Iyer C., Kosters A., Sethi G., Kunnumakkara A.B., Aggarwal B.B., and Versalovic J. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. Cell Microbiol. 10 7 (2008) 1442-1452
26. Jijon H., Backer J., Diaz H., Yeung H., Theil D., McKaigney C., DeSimone C., and Madsen K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 126 (2004) 1358-1373
27. Johnson-Henry K.C., Nadjafi M., Avitzur Y., Mitchell D.J., Ngan B.Y., Galindo-Mata E., Jones N.L., and Sherman P.M. Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. J. Infect. Dis. 191 12 (2005) 2106-2117
28. Kajander K., Myllyluoma E., Rajilic-Stojanovic M., Kyronpalo S., Rasmussen M., Jarvenpaa S., Zoetendal E.G., de Vos W.M., Vapaatalo H., and Korpela R. Clinical trial: Multispecies probiotic supllementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment. Pharmacol. Ther. 27 1 (2008) 48-57
29. Kelly D., Campbell J.I., King T.P., Grant G., Jansson E.A., Coutts A.G., Petersson S., and Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat. Immunol. 5 1 (2004) 104-112
30. Kim J.M., Kim J.S., Kim Y.J., Oh Y.K., Kim I.Y., Chee Y.J., Han J.S., and Jung H.C. Conjugated linoleic acids produced by Lactobacillus dissociates IKK-γ and Hsp90 complex in Helicobacter pylori-infected gastric epithelial cells. Lab. Invest. 88 5 (2008) 541-542
31. Lavermicocca P., Valerio F., Lonigro S.L., Di Leo A., and Visconti A. Antagonistic activity of potential probiotic Lactobacilli against the ureolytic pathogen Yersinia enterocolitica. Curr. Microbiol. 56 2 (2008) 175-181
32. Mack D.R., Michail S., Wel S., McDougall L., and Hollingsworth M.A. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am. J. Physiol. 276 4 (1999) G941-G950
33. Mack D.R., Ahrne S., Hyde L., Wei S., and Hollingsworth M.A. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 52 (2003) 827-833
34. Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., Yachimec C., Doyle J., Jewell L., and DeSimone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121 3 (2001) 580-591
35. Mattar A.F., Teitelbaum D.H., Drongowski R.A., Yongyi F., Harmon C.M., and Coran A.G. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr. Surg. Int. 18 (2002) 586-590
36. Medellin-Pena M.J., Wang H., Johnson R., Anand S., and Griffiths M.W. Probiotics affect virulence-related gene expression in Escherichia coli O157:H7. Appl. Environ. Microbiol. 73 13 (2007) 4259-4267
37. Menard S., Candalh C., Bambou J.C., Terpend K., Cerf-Bensussan N., and Heyman M. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53 (2004) 821-828
38. Miettinen M., Lehtonen A., Julkunen I., and Matikainen S. Lactobacilli and streptococci activate NF-κB and STAT signalling pathways in human macrophages. J. Immunol. 164 (2000) 3733-3740
39. O'Hara A.M., and Shanahan F. Gut microbiota: Mining for therapeutic potential. Clin. Gastroenterol. Hepatol. 5 3 (2007) 274-284
40. O'Hara A.M., O'Regan P., Fanning A., O'Mahony C., MacSharry J., Lyons A., Bienenstock J., O'Mahony L., and Shanahan F. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology 118 (2006) 202-215
41. O'Mahony L., Feeney M., O'Halloran S., Murphy L., Kiely B., Fitzgibbon J., Lee G., O'Sullivan G., Shanahan F., and Collins J.K. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment. Pharmacol. Ther. 15 (2001) 1219-1225
42. Pridmore R.D., Pittet A.C., Praplan F., and Cavadini C. Hydrogen peroxide production by Lactobacillus johnsonii NCC 533 and its role in anti-Salmonella activity. FEMS Microbiol. Lett. 283 2 (2008) 210-215
43. Pronio A., Montesani C., Butteroni C., Vecchione S., Mumolo G., Vestri A., Vitolo D., and Boirivant M. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel Dis. 14 5 (2008) 662-668
44. Qin H.L., Shen T.Y., Gao Z.G., Fan X.B., Hang X.M., Jiang Y.Q., and Zhang H.Z. Effect of lactobacillus on the gut microflora and barrier function of the rats with abdominal infection. World J. Gastroenterol. 11 17 (2005) 2591-2596
45. Rolfe R.D. The role of probiotic cultures in the control of gastrointestinal health. J. Nutr. 130 (2000) 396S-402S
46. Sartor R.B. Targeting enteric bacteria in treatment of inflammatory bowel diseases: Why, how and when. Curr. Opin. Gastroenterol. 19 4 (2003) 358-365
47. Sartor R.B. Probiotic therapy of intestinal inflammation and infections. Curr. Opin. Gastroenterol. 21 (2004) 44-50
48. Savaiano D.A., AbouElAnour A., Smith D.E., and Levitt M.D. Lactose malabsorption from yogurt, pasteurized yogurt, sweet acidophilus milk, and cultured milk in lactase-deficient individuals. Am. J. Clin. Nutr. 40 6 (1984) 1219-1223
49. Schlee M., Harder J., Koten B., Stange E.F., Wehkamp J., and Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2. Clin. Exp. Immunol. 151 3 (2008) 528-535
50. Sechi L.A., Mura M., Tanda E., Lissia A., Fadda G., and Zanetti S. Mycobacterium avium sub. paratuberculosis in tissue samples of Crohn's disease patients. New Microbiol. 27 1 (2004) 75-77
51. Senok A.C., Ismaeel A.Y., and Botta G.A. Probiotics: Facts and myths. Clin. Microbiol. Infect. 11 (2005) 958-966
52. Shanahan F. Probiotics in inflammatory bowel disease. Gut 48 5 (2001) 609
53. Sherman P.M., Johnson-Henry K.C., Yeung H.P., Ngo P.S.C., Goulet J., and Tompkins T.A. Probiotics reduce Enterohemorrhagic Escherichia coli O157:H7- and Enteropathogenic Escherichia coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect. Immun. 73 8 (2005) 5183-5188
54. Silva A.M., Barbosa F.H., Duarte R., Vieira L.Q., Arantes R.M., and Nicoli J.R. Effect of Bifidobacterium longum ingestion on experimental salmonellosis in mice. J. Appl. Microbiol. 97 1 (2004) 29-37
55. Smith L., Orugunty R.S., and Hillman J.D. In: Riley M.A., and Gillor O. (Eds). Research and Applications in Bacteriocins (2006), Horizon Bioscience, Norfolk, UK
56. Torii A., Torii S., Fujiwara S., Tanaka H., Inagaki N., and Nagai H. Lactobacillus acidophilus strain L-92 regulates the production of Th1 cytokine as well as Th2 cytokines. Allergol. Int. 56 3 (2007) 293-301
57. Toure R., Kheadr E., Lacroix C., Maroni O., and Fliss I. Production of antibacterial substances by Bifidobacterial isolates from infant stool active against Listeria moncytogenes. J. Appl. Microbiol. 95 5 (2003) 1058-1069
58. Tsai C.C., Hsih H.Y., Chiu H.H., Lai Y.Y., Liu J.H., Yu B., and Tsen H.Y. Antagonistic activity against Salmonella infection in vitro and in vivo for two Lactobacillus strains from swine and poultry. Int. J. Food. Microbiol. 102 (2005) 185-194
59. Venturi A., Gionchetti P., Rizzello F., Johansson R., Zucconi E., Brigidi P., Matteuzzi D., and Campieri M. Impact on the composition of the fecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. 13 (1999) 1103-1108
60. Wehkamp J., Harder J., Wehkamp K., Wehkamp-von Meissner B., Schlee M., Enders C., Sonnenborn U., Nuding S., Bengmark S., Fellermann K., Schroder J.M., and Stange E.F. NF-κB- and AP-1-mediated induction of human β-defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: A novel effect of a probiotic bacterium. Infect. Immun. 72 10 (2004) 5750-5758
61. Zhu W.M., Liu W., and Wu D.Q. Isolation and characterization of a new bacteriocin from Lactobacillus gasseri KT7. J. Appl. Micro. 88 (2000) 877-886
62. Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., and Schmidt M.A. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol. 9 3 (2007) 804-816